相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Essential role of protein tyrosine phosphatase 1B in obesity-induced inflammation and peripheral insulin resistance during aging
Agueda Gonzalez-Rodriguez et al.
AGING CELL (2012)
Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
Michael A. Nauck
AMERICAN JOURNAL OF MEDICINE (2011)
Sitagliptin prevents the development of metabolic and hormonal disturbances, increased beta-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats
Barbara Maiztegui et al.
CLINICAL SCIENCE (2011)
Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice
Jun Shirakawa et al.
DIABETES (2011)
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
M. -R. Taskinen et al.
DIABETES OBESITY & METABOLISM (2011)
The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus
T. Forst et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study
R. Gomis et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
S. Del Prato et al.
DIABETES OBESITY & METABOLISM (2011)
Linagliptin In Type 2 Diabetes Mellitus
Lesley J. Scott
DRUGS (2011)
Insulin Resistance in Nonalcoholic Fatty Liver Disease
E. Bugianesi et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors
A. J. Scheen
DIABETES OBESITY & METABOLISM (2010)
The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
Stefan Blech et al.
DRUG METABOLISM AND DISPOSITION (2010)
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
Carolyn F. Deacon et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Liver-Specific Suppressor of Cytokine Signaling-3 Deletion in Mice Enhances Hepatic Insulin Sensitivity and Lipogenesis Resulting in Fatty Liver and Obesity
Nirupa Sachithanandan et al.
HEPATOLOGY (2010)
Myeloid Cell-Restricted Insulin Receptor Deficiency Protects Against Obesity-Induced Inflammation and Systemic Insulin Resistance
Jan Mauer et al.
PLOS GENETICS (2010)
Thiazolidinediones and the liver in humans
Hannele Yki-Jarvinen
CURRENT OPINION IN LIPIDOLOGY (2009)
Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients
T. Heise et al.
DIABETES OBESITY & METABOLISM (2009)
Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans
Holger Fuchs et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2009)
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes
Koichiro Azuma et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
Leo Thomas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment
Wook Kim et al.
PHARMACOLOGICAL REVIEWS (2008)
Dipeptidyl peptidase-4 inhibitors -: Clinical data and clinical implications
Bo Ahren
DIABETES CARE (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Mechanisms of Disease: hepatic steatosis in type 2 diabetes - pathogenesis and clinical relevance
Michael Roden
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2006)
Incretins, insulin secretion and Type 2 diabetes mellitus
T Vilsboll et al.
DIABETOLOGIA (2004)
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
JJ Holst et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system
PL Brubaker et al.
ENDOCRINOLOGY (2004)
Glucagon-like peptide-1 prevents beta cell glucolipotoxicity
J Buteau et al.
DIABETOLOGIA (2004)
Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets
L Farilla et al.
ENDOCRINOLOGY (2003)
Cultured pancreatic ductal cells undergo cell cycle re-distribution and β-cell-like differentiation in response to glucagon-like peptide-1
A. Bulotta et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2002)
Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats
JA Pospisilik et al.
DIABETES (2002)
Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas
DA Stoffers et al.
DIABETES (2000)
分享论文
